Report Detail
Global Primary Myelofibrosis Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4742496 |
- 28 September, 2026 |
- Global |
- 88 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Primary Myelofibrosis Drug market size was valued at US$ 172 million in 2025 and is forecast to a readjusted size of US$ 321 million by 2032 with a CAGR of 9.4% during review period.
Primary myelofibrosis (MF) is a chronic blood cancer in which excessive scar tissue forms in the bone marrow and impairs its ability to produce normal blood cells. Researchers believe MF may be caused by abnormal blood stem cells in the bone marrow. The abnormal stem cells produce mature cells that grow quickly and take over the bone marrow, causing both fibrosis (scar tissue formation) and chronic inflammation.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Primary Myelofibrosis Drug market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Primary Myelofibrosis Drug market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Primary Myelofibrosis Drug market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Primary Myelofibrosis Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Primary Myelofibrosis Drug market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Primary Myelofibrosis Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Primary Myelofibrosis Drug market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, AbbVie, Novartis, Celgene, Grunenthal, Incyte, CTI BioPharma, Bristol Myers Squibb, Suzhou Zelgen Biopharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Primary Myelofibrosis Drug market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
JAK 1
JAK 2
Others
Market segment by Application
Adults
Children
Major players covered
GSK
AbbVie
Novartis
Celgene
Grunenthal
Incyte
CTI BioPharma
Bristol Myers Squibb
Suzhou Zelgen Biopharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Primary Myelofibrosis Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Primary Myelofibrosis Drug, with price, sales quantity, revenue, and global market share of Primary Myelofibrosis Drug from 2021 to 2026.
Chapter 3, the Primary Myelofibrosis Drug competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Primary Myelofibrosis Drug breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Primary Myelofibrosis Drug market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Primary Myelofibrosis Drug.
Chapter 14 and 15, to describe Primary Myelofibrosis Drug sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Primary Myelofibrosis Drug Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 JAK 1
- 1.3.3 JAK 2
- 1.3.4 Others
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global Primary Myelofibrosis Drug Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Adults
- 1.4.3 Children
- 1.5 Global Primary Myelofibrosis Drug Market Size & Forecast
- 1.5.1 Global Primary Myelofibrosis Drug Consumption Value (2021 & 2025 & 2032)
- 1.5.2 Global Primary Myelofibrosis Drug Sales Quantity (2021-2032)
- 1.5.3 Global Primary Myelofibrosis Drug Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 GSK
- 2.1.1 GSK Details
- 2.1.2 GSK Major Business
- 2.1.3 GSK Primary Myelofibrosis Drug Product and Services
- 2.1.4 GSK Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 GSK Recent Developments/Updates
- 2.2 AbbVie
- 2.2.1 AbbVie Details
- 2.2.2 AbbVie Major Business
- 2.2.3 AbbVie Primary Myelofibrosis Drug Product and Services
- 2.2.4 AbbVie Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 AbbVie Recent Developments/Updates
- 2.3 Novartis
- 2.3.1 Novartis Details
- 2.3.2 Novartis Major Business
- 2.3.3 Novartis Primary Myelofibrosis Drug Product and Services
- 2.3.4 Novartis Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Novartis Recent Developments/Updates
- 2.4 Celgene
- 2.4.1 Celgene Details
- 2.4.2 Celgene Major Business
- 2.4.3 Celgene Primary Myelofibrosis Drug Product and Services
- 2.4.4 Celgene Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Celgene Recent Developments/Updates
- 2.5 Grunenthal
- 2.5.1 Grunenthal Details
- 2.5.2 Grunenthal Major Business
- 2.5.3 Grunenthal Primary Myelofibrosis Drug Product and Services
- 2.5.4 Grunenthal Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Grunenthal Recent Developments/Updates
- 2.6 Incyte
- 2.6.1 Incyte Details
- 2.6.2 Incyte Major Business
- 2.6.3 Incyte Primary Myelofibrosis Drug Product and Services
- 2.6.4 Incyte Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 Incyte Recent Developments/Updates
- 2.7 CTI BioPharma
- 2.7.1 CTI BioPharma Details
- 2.7.2 CTI BioPharma Major Business
- 2.7.3 CTI BioPharma Primary Myelofibrosis Drug Product and Services
- 2.7.4 CTI BioPharma Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 CTI BioPharma Recent Developments/Updates
- 2.8 Bristol Myers Squibb
- 2.8.1 Bristol Myers Squibb Details
- 2.8.2 Bristol Myers Squibb Major Business
- 2.8.3 Bristol Myers Squibb Primary Myelofibrosis Drug Product and Services
- 2.8.4 Bristol Myers Squibb Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Bristol Myers Squibb Recent Developments/Updates
- 2.9 Suzhou Zelgen Biopharmaceuticals
- 2.9.1 Suzhou Zelgen Biopharmaceuticals Details
- 2.9.2 Suzhou Zelgen Biopharmaceuticals Major Business
- 2.9.3 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Product and Services
- 2.9.4 Suzhou Zelgen Biopharmaceuticals Primary Myelofibrosis Drug Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 Suzhou Zelgen Biopharmaceuticals Recent Developments/Updates
3 Competitive Environment: Primary Myelofibrosis Drug by Manufacturer
- 3.1 Global Primary Myelofibrosis Drug Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Primary Myelofibrosis Drug Revenue by Manufacturer (2021-2026)
- 3.3 Global Primary Myelofibrosis Drug Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Primary Myelofibrosis Drug by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Primary Myelofibrosis Drug Manufacturer Market Share in 2025
- 3.4.3 Top 6 Primary Myelofibrosis Drug Manufacturer Market Share in 2025
- 3.5 Primary Myelofibrosis Drug Market: Overall Company Footprint Analysis
- 3.5.1 Primary Myelofibrosis Drug Market: Region Footprint
- 3.5.2 Primary Myelofibrosis Drug Market: Company Product Type Footprint
- 3.5.3 Primary Myelofibrosis Drug Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Primary Myelofibrosis Drug Market Size by Region
- 4.1.1 Global Primary Myelofibrosis Drug Sales Quantity by Region (2021-2032)
- 4.1.2 Global Primary Myelofibrosis Drug Consumption Value by Region (2021-2032)
- 4.1.3 Global Primary Myelofibrosis Drug Average Price by Region (2021-2032)
- 4.2 North America Primary Myelofibrosis Drug Consumption Value (2021-2032)
- 4.3 Europe Primary Myelofibrosis Drug Consumption Value (2021-2032)
- 4.4 Asia-Pacific Primary Myelofibrosis Drug Consumption Value (2021-2032)
- 4.5 South America Primary Myelofibrosis Drug Consumption Value (2021-2032)
- 4.6 Middle East & Africa Primary Myelofibrosis Drug Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Primary Myelofibrosis Drug Sales Quantity by Type (2021-2032)
- 5.2 Global Primary Myelofibrosis Drug Consumption Value by Type (2021-2032)
- 5.3 Global Primary Myelofibrosis Drug Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Primary Myelofibrosis Drug Sales Quantity by Application (2021-2032)
- 6.2 Global Primary Myelofibrosis Drug Consumption Value by Application (2021-2032)
- 6.3 Global Primary Myelofibrosis Drug Average Price by Application (2021-2032)
7 North America
- 7.1 North America Primary Myelofibrosis Drug Sales Quantity by Type (2021-2032)
- 7.2 North America Primary Myelofibrosis Drug Sales Quantity by Application (2021-2032)
- 7.3 North America Primary Myelofibrosis Drug Market Size by Country
- 7.3.1 North America Primary Myelofibrosis Drug Sales Quantity by Country (2021-2032)
- 7.3.2 North America Primary Myelofibrosis Drug Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Primary Myelofibrosis Drug Sales Quantity by Type (2021-2032)
- 8.2 Europe Primary Myelofibrosis Drug Sales Quantity by Application (2021-2032)
- 8.3 Europe Primary Myelofibrosis Drug Market Size by Country
- 8.3.1 Europe Primary Myelofibrosis Drug Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Primary Myelofibrosis Drug Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Primary Myelofibrosis Drug Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Primary Myelofibrosis Drug Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Primary Myelofibrosis Drug Market Size by Region
- 9.3.1 Asia-Pacific Primary Myelofibrosis Drug Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Primary Myelofibrosis Drug Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Primary Myelofibrosis Drug Sales Quantity by Type (2021-2032)
- 10.2 South America Primary Myelofibrosis Drug Sales Quantity by Application (2021-2032)
- 10.3 South America Primary Myelofibrosis Drug Market Size by Country
- 10.3.1 South America Primary Myelofibrosis Drug Sales Quantity by Country (2021-2032)
- 10.3.2 South America Primary Myelofibrosis Drug Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Primary Myelofibrosis Drug Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Primary Myelofibrosis Drug Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Primary Myelofibrosis Drug Market Size by Country
- 11.3.1 Middle East & Africa Primary Myelofibrosis Drug Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Primary Myelofibrosis Drug Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Primary Myelofibrosis Drug Market Drivers
- 12.2 Primary Myelofibrosis Drug Market Restraints
- 12.3 Primary Myelofibrosis Drug Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Primary Myelofibrosis Drug and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Primary Myelofibrosis Drug
- 13.3 Primary Myelofibrosis Drug Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Primary Myelofibrosis Drug Typical Distributors
- 14.3 Primary Myelofibrosis Drug Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Primary Myelofibrosis Drug. Industry analysis & Market Report on Primary Myelofibrosis Drug is a syndicated market report, published as Global Primary Myelofibrosis Drug Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Primary Myelofibrosis Drug market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
